Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-06-22

FDA Approved: APTIVUS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for APTIVUS (tipranavir) by Boehringer Ingelheim Pharmaceuticals, expanding its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aptivus (tipranavir)

Snippet

SUPPL AP for APTIVUS (TIPRANAVIR)